Ngenla
Evidence Grade A — Regulatory approved. 60 published studies. 9 registered clinical trials.
Loading...
Somatrogon (sold as Ngenla) is a once-weekly growth hormone injection for children with growth hormone deficiency — reducing the injection burden from 365 times per year to 52. For children who may need years of treatment, this represents a significant improvement in daily quality of life and treatment adherence.
60 published studies: 31 human, 0 animal, 0 in-vitro, 24 reviews
Somatrogon is marketed as Ngenla (approved June 2023) for paediatric growth hormone deficiency in children aged 3 years and older. In the pivotal trial, once-weekly somatrogon produced growth rates equivalent to daily somatropin injections (10.1 cm/year versus 9.8 cm/year), confirming that reducing injection frequency does not compromise growth outcomes.
Ngenla represents a meaningful advance for paediatric patients and their families, reducing injections from 365 to 52 per year. Treatment adherence has been a persistent challenge with daily growth hormone, and weekly dosing is expected to improve long-term outcomes through better compliance. Somatrogon competes directly with somapacitan (Sogroya), the other approved weekly growth hormone, creating a new generation of less burdensome treatment options.
Somatrogon works through the same growth hormone receptor as the body's natural growth hormone and as daily somatropin. The difference is in its molecular design: human growth hormone has been fused with segments from another hormone (hCG) that contain sugar-coated attachment points. These sugar molecules prevent the kidneys from clearing the drug quickly, extending its duration from hours to about a week. The result is sustained growth hormone activity from a single weekly injection.
The pivotal trial showed that once-weekly somatrogon produced growth rates equivalent to daily somatropin (10.1 cm/year versus 9.8 cm/year), confirming that reducing injection frequency does not sacrifice growth outcomes. Treatment adherence has been a persistent challenge with daily growth hormone injections, and weekly dosing is expected to improve long-term outcomes. Ngenla is currently approved only for paediatric growth hormone deficiency (not adults), whereas the competing weekly product somapacitan (Sogroya) covers both adults and children. The paediatric growth hormone market is now actively transitioning from daily to weekly formulations. Long-term safety surveillance and potential expansion to other growth conditions (Turner syndrome, children born small for gestational age) are ongoing.
Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels
Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.
A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.
Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone
Ngenla Subcutaneous Injection Special Investigation
EMA Marketing Authorisation
Health Canada Market Authorisation
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 3
FDA SUPPL 6
Somatropin has been available since the mid-1980s and is one of the most established peptide therapies. It is sold under numerous brand names including Genotropin, Humatrope, Norditropin, and Omnitrope (the first biosimilar approved in the US, 2006). Approved indications include childhood and adult growth hormone deficiency, Turner syndrome, children born small for gestational age, Prader-Willi syndrome, idiopathic short stature, and short stature from chronic kidney disease. Daily injection has been the main burden of somatropin therapy, particularly for paediatric patients who may require years of treatment. This has driven the development of once-weekly alternatives (somatrogon and somapacitan), which are gradually changing the treatment landscape. Annual treatment costs remain substantial, and concerns about misuse in anti-ageing and performance enhancement contexts are ongoing.
Tesamorelin is marketed as Egrifta SV (approved November 2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In clinical trials, it reduced visceral fat by approximately 15% compared to a 5% increase with placebo, and this reduction was sustained with continued treatment. Tesamorelin occupies a unique niche — it is the only approved GHRH analogue and the only medication specifically approved for HIV-associated lipodystrophy. Beyond its approved indication, it has attracted research interest for potential effects on liver fat, cognitive function, and peripheral neuropathy. Fat reduction reverses when treatment stops, and it is not approved for general weight loss or body composition purposes.
Sermorelin was formerly marketed as Geref (Serono) before voluntary withdrawal in 2009. The FDA confirmed the withdrawal was not related to safety or effectiveness. Research suggests it remains one of the most commonly prescribed compounds through US compounding pharmacies, particularly in anti-ageing and hormone optimisation clinics. Research suggests sermorelin's appeal lies in its more physiological approach to growth hormone enhancement compared to direct growth hormone injection — it preserves pulsatile release and feedback regulation. However, clinical evidence for its use in adults outside the original paediatric growth hormone deficiency indication is limited, and its very short half-life requiring daily injection is a practical limitation. Compounding pharmacy formulations are not subject to the same regulatory oversight as FDA-approved products.
